Overview
The purpose of this study is to evaluate the combined effects of non-invasive neuromodulation (specifically transauricular Vagus Nerve Stimulation) with exercise interventions to improve physical function and quality of life in individuals with Parkinson's Disease.
Description
During this clinical trial, participants will be randomized into two groups, with half of the participants assigned to GROUP 1: active taVNS + exercise, and half of the participants assigned to GROUP 2: sham taVNS + exercise. The active taVNS + exercise group will receive 15 minutes of active taVNS prior to treatment. Participants who are randomized into the sham taVNS + exercise group will receive 0 mA of current for 15 minutes prior to treatment. All participants will be guided through exercises by an exercise specialist, which will include:
- intensive exercises that focus on increasing the size and amplitude of movements; 2) task-specific practice, which involves practicing functional tasks, such as dressing, bathing, and cooking, in order to transfer the gains made in therapy to real-life situations;
- a home program, which consists of exercises and tasks that the patient can do on their own and performed nightly, and 4) group yoga sessions. The exercise intervention proposed involves the supervision of a trained exercise specialist at all times during the treatment session. Exercise will be provided in a clinical setting, 60 minutes per session, up to 3 sessions/week, for 4 weeks total.
Eligibility
Inclusion Criteria:
- age between 35 and 80 years
- no walking aids
- stable medication 4 weeks prior to and during the study
- no falls in the past 6 months
- participant must have MD who is willing to provide oversight and approval for clinically defined "off" state
Exclusion Criteria:
- mild cognitive impairment (MoCA <25)
- self reported depression
- antidepressive or antipsychotic medication
- participation in a VNS study in the past year
- disabling bradykinesia to ensure patients are able to participate in intensive physiotherapy (based on clinical impression and in accordance to UPDRS part III item 14 - to be administered in clinic)
- prior history of cardiovascular, neurological or musculoskeletal disorders known to interfere with testing PD features
- implanted medical device of any type
- history of seizures
- peripheral neuropathy including temporal mandibular disorders and Bells Palsy, and
- vasovagal syncope.